Study Title: SWOG S0016
Category: Cancer, General
Currently accepting participants?
Not at this time.
Principal Investigator: Jacqueline Vuky
Study Coordinator: Gail Chumbley
Phone: (206) 223-6892 Ext.36892
Email: gchumbley@benaroyaresearch.org
What is the SWOG S0016 study?
Arm 1: CHOP (Cyclophosphamide, Doxorubicin, Predinison, Vincristine) + Rituximab Arm 2: CHOP + Tositumomab + I-131 Tositumomab
Who can participate?
Eligibiligy: ~Untreated Follicular Non-Hodgkin's Lymphoma ~Lymphoma must express CD20 antigen ~Must have bidemensional measurable disease ~Must have Stage III, Stage IV or bulky Stage II Ineligibilty: ~Must not be HIV positive ~Pregnant or nursing women are ineligible ~No prior malignancy within the last 5 years
Study Summary:
"A Phase II Trial of Chop + RItuximan vs. Chop+ iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatemtn of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas"
Detailed Study Description:
Study Design: Interventional
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Follicular Non-Hodgkin's Lymphoma
Intervention Type: Monoclonal Antibody
Intervention Name: Tositumomab
Gender: Male and Female
Age group: Interventional
Sponsor: Southwest Oncology Group (SWOG)
Other studies in this category include:
Studies currently accepting study participants:
Studies currently not accepting study participants:
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- MK0646 for Patients with Advanced Cancer
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer